Thomas Tibbitts, Ph. D promoted to Senior Vice President for Computational Discovery
Thomas Tibbitts, PhD has been promoted to Senior Vice President for Computational Discovery at Goldfinch Bio reporting to the CEO. In this new role, Thomas will continue to be responsible for the strategy and execution of building world-class infrastructure and other support of the Kidney Genome Atlas (KGATM) for Goldfinch’s mission of delivering precision medicines for patients with kidney diseases.
Thomas has been an integral part of the Goldfinch team since its inception at Third Rock Ventures in 2016. As the architect of the KGA, he rapidly established key collaborations with four major academic research institutions to gain access to patient clinical profiles and samples for genomic and transcriptomic sequencing, and then led the effort to create the world’s most comprehensive database of its kind for kidney diseases. The continued rapid expansion and interrogation of the KGA at Goldfinch Bio will provide valuable disease insights, new drug targets and patient stratification for clinical trials.
Prior to joining Goldfinch, Thomas spent eleven years at Infinity Pharmaceuticals, building genomic and transcriptomic capabilities for analysis of clinical samples across multiple oncology drug discovery and development programs, including duvelisib (Copiktra), a new drug recently approved as a treatment for hematologic malignancies.